<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Gastroenterol Hepatol</journal-id><journal-id journal-id-type="iso-abbrev">Clin Gastroenterol Hepatol</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association</journal-title></journal-title-group><issn pub-type="ppub">1542-3565</issn><issn pub-type="epub">1542-7714</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10709527</article-id><article-id pub-id-type="pmcid-ver">PMC10709527.319</article-id><article-id pub-id-type="pmcaid">10709527</article-id><article-id pub-id-type="pmcaiid">10709527</article-id><article-id pub-id-type="manuscript-id">NIHMS1909224</article-id><article-id pub-id-type="pmid">37302445</article-id><article-id pub-id-type="doi">10.1016/j.cgh.2023.05.024</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1909224</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1909224</article-id><article-version article-version-type="pmc-version">319</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Hepatocellular Carcinoma Incidence Threshold for Surveillance in Virologically Cured Hepatitis C Individuals</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Chhatwal</surname><given-names initials="J">Jagpreet</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hajjar</surname><given-names initials="A">Ali</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mueller</surname><given-names initials="PP">Peter P</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nemutlu</surname><given-names initials="G">Gizem</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kulkarni</surname><given-names initials="N">Neeti</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Peters</surname><given-names initials="MLB">Mary Linton B</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kanwal</surname><given-names initials="F">Fasiha</given-names></name><xref rid="A6" ref-type="aff">6</xref><xref rid="A7" ref-type="aff">7</xref></contrib></contrib-group><aff id="A1"><label>1</label>Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, MA</aff><aff id="A2"><label>2</label>Dana Farber / Harvard Cancer Center, Boston, MA</aff><aff id="A3"><label>3</label>Liver Center and Gastrointestinal Division, Massachusetts General Hospital, Boston, MA</aff><aff id="A4"><label>4</label>Brandeis International Business School, Brandeis University, Boston, MA</aff><aff id="A5"><label>5</label>Division of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA</aff><aff id="A6"><label>6</label>Department of Medicine, Baylor College of Medicine, Houston, TX</aff><aff id="A7"><label>7</label>Houston Veterans Affairs Health Services Research and Development Center of Excellence, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX</aff><author-notes><fn fn-type="con" id="FN1"><p id="P1">Author contributions:</p><p id="P2"><italic toggle="yes">study concept and design</italic>: Chhatwal, Hajjar, Kanwal, <italic toggle="yes">acquisition of data</italic>: Chhatwal, Hajjar, Mueller</p><p id="P3"><italic toggle="yes">analysis and interpretation of data</italic>: Chhatwal, Hajjar, Mueller, Nemutlu, Kulkarni, Peters, Kanwal <italic toggle="yes">drafting of the manuscript</italic>: Chhatwal, Hajjar</p><p id="P4"><italic toggle="yes">critical revision of the manuscript for important intellectual content</italic>: Chhatwal, Hajjar, Mueller, Nemutlu, Kulkarni, Peters, Kanwal</p><p id="P5"><italic toggle="yes">statistical analysis:</italic> Hajjar, Mueller</p><p id="P6"><italic toggle="yes">obtained funding:</italic> Chhatwal, Kanwal</p><p id="P7"><italic toggle="yes">study supervision:</italic> Chhatwal</p></fn><corresp id="CR1"><bold>Correspondence:</bold> Jagpreet Chhatwal, PhD, MGH Institute for Technology Assessment, 101 Merrimac Street, Ste 1010, Boston, MA 02114, <email>jagchhatwal@mgh.harvard.edu</email>, Phone: (617) 724-4445; Fax: (617) 726-9414</corresp></author-notes><pub-date pub-type="ppub"><month>1</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>09</day><month>6</month><year>2023</year></pub-date><volume>22</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">450672</issue-id><fpage>91</fpage><lpage>101.e6</lpage><pub-history><event event-type="nihms-submitted"><date><day>18</day><month>06</month><year>2023</year></date></event><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>01</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-01-01 00:26:13.670"><day>01</day><month>01</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1909224.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background &amp; Aims:</title><p id="P8">Guidelines recommend biannual surveillance for hepatocellular carcinoma (HCC) in hepatitis C individuals with cirrhosis if the HCC incidence rate is above 1.5 per 100 person-years (PY). However, the incidence threshold for surveillance in individuals who achieve a virological cure is unknown. We estimated the HCC incidence rate above which routine HCC surveillance is cost-effective in this growing population of virologically-cured hepatitis C individuals with cirrhosis or advanced fibrosis.</p></sec><sec id="S2"><title>Methods:</title><p id="P9">We developed a Markov-based microsimulation model of the natural history of HCC in individuals with hepatitis C who achieved virological cure with oral direct-acting antivirals. We used published data on the natural history of hepatitis C, competing risk post virological cure, HCC tumor progression, real-world HCC surveillance adherence, contemporary HCC treatment options and associated costs, and utilities of different health states. We estimated the HCC incidence above which biannual HCC surveillance using ultrasound and alpha-fetoprotein would be cost-effective.</p></sec><sec id="S3"><title>Results:</title><p id="P10">In virologically-cured hepatitis C individuals with cirrhosis or advanced fibrosis, HCC surveillance is cost-effective if HCC incidence exceeds 0.7 per 100-PY using $100,000 per quality-adjusted life-year (QALY) willingness-to-pay. At this HCC incidence, routine HCC surveillance would result in 2,650 and 5,700 additional life-years per 100,000 cirrhosis and advanced fibrosis persons, respectively, compared to no surveillance. At $150,000 willingness-to-pay, surveillance is cost-effective if HCC incidence exceeds 0.4 per 100-PY. Sensitivity analysis showed that the threshold mostly remained below 1.5 per 100-PY.</p></sec><sec id="S4"><title>Conclusion:</title><p id="P11">The contemporary HCC incidence threshold is much lower than the previous 1.5% incidence value used to guide HCC surveillance decisions. Updating clinical guidelines could improve the early diagnosis of HCC.</p></sec></abstract><abstract id="ABS2" abstract-type="graphical"><title>Graphical Abstract</title><p id="P200">
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="nihms-1909224-f0006.jpg"/>
</p></abstract><kwd-group><kwd>liver cancer</kwd><kwd>screening</kwd><kwd>cost-effectiveness analysis</kwd><kwd>prevention</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>